Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res. 2006 Aug 28
The prevention and control of disease caused by seasonal and potential pandemic influenza viruses is currently managed by the use influenza vaccines and antivirals. The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used extensively in some countries. Since the early 2000s increased resistance to these drugs has been reported especially in the A(H3) viruses. In this study we analysed recent human influenza A strains isolated in Australia and regionally for evidence of resistance to adamantanes and found evidence of significant resistant emerging during 2005.
See Also:
Latest articles in those days:
- Host Species Contribution to the Spatiotemporal Dynamics of the 2024-2025 H5N1 Epidemic in Italy 12 hours ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans 12 hours ago
- Molecular surveillance and predictive risk modelling of avian influenza virus in wild birds in Egypt 13 hours ago
- Germany as a key transit hub for the emergence and spread of high pathogenicity avian influenza H5 clade 2.3.4.4b reassortants in Europe 2 days ago
- Degradation of ACSL3 by influenza A virus shifts unfolded protein response from antiviral defense to viral evasion 2 days ago
[Go Top] [Close Window]


